This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)
All three working simultaneously creates a fat loss environment that no single or dual mechanism can replicate
Higher concentrations are more compact
Support healthy weight management with a simple-to-take oral spray taken twice daily
Retatrutide (CAS 2381089-83-2) is a triple-agonist peptide that engages three receptors simultaneously the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor making it one of the most-studied multi-receptor metabolic peptides currently in the research literature
If you adhere to the prescribed program, research shows that many patients lose about 15 to 20 percent of their initial body weight over six months